These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22647638)

  • 21. Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on Crohn's disease: a real-life survey in Spain.
    Hinojosa J; Gisbert JP; Gomollón F; López San Román A
    J Crohns Colitis; 2012 Aug; 6(7):763-70. PubMed ID: 22398092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn's disease patients.
    Ishida K; Inoue T; Fujiwara K; Sakanaka T; Narabayashi K; Nouda S; Okada T; Kakimoto K; Kuramoto T; Kawakami K; Abe Y; Takeuchi T; Murano M; Tokioka S; Umegaki E; Higuchi K
    World J Gastroenterol; 2013 May; 19(17):2676-82. PubMed ID: 23674875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study.
    Papamichael K; Archavlis E; Lariou C; Mantzaris GJ
    J Crohns Colitis; 2012 Oct; 6(9):924-31. PubMed ID: 22424843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pulmonary cryptococcosis in childhood systemic lupus erythematosus and Sjögren syndrome overlap: a rare opportunistic infection.
    Marques VL; Gomes RC; Viola GR; Maia MM; Durigon GS; Aikawa NE; Artur Silva C
    Lupus; 2013 Nov; 22(13):1409-12. PubMed ID: 23985965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Colitis as a manifestation of infliximab-associated disseminated cryptococcosis.
    Osawa R; Singh N
    Int J Infect Dis; 2010 May; 14(5):e436-40. PubMed ID: 19660974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Adalimumab for the treatment of Crohn's disease - consensus paper of the Working Group "chronic inflammatory bowel diseases" of the Austrian Society for Gastroenterology and Hepatology].
    Reinisch W; Haas T; Kaser A; Petritsch W; Vogelsang H; Feichtenschlager T; Novacek G; Siebert F; Tilg H; Knoflach P
    Z Gastroenterol; 2009 Apr; 47(4):372-80. PubMed ID: 19358065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
    Loftus EV; Feagan BG; Colombel JF; Rubin DT; Wu EQ; Yu AP; Pollack PF; Chao J; Mulani P
    Am J Gastroenterol; 2008 Dec; 103(12):3132-41. PubMed ID: 18853973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adalimumab reversed a severe lymphopenia in a patient with Crohn's disease.
    Taxonera C; Mendoza JL; Ortega L; Pérez MI; Díaz-Rubio M
    J Crohns Colitis; 2012 May; 6(4):488-91. PubMed ID: 22398051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute coronary syndrome in a Crohn's disease patient treated with adalimumab.
    Petitpain N; Bornert-Keller N; Peyrin-Biroulet L
    J Crohns Colitis; 2013 Oct; 7(9):e396. PubMed ID: 23523265
    [No Abstract]   [Full Text] [Related]  

  • 30. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
    Dewint P; Hansen BE; Verhey E; Oldenburg B; Hommes DW; Pierik M; Ponsioen CI; van Dullemen HM; Russel M; van Bodegraven AA; van der Woude CJ
    Gut; 2014 Feb; 63(2):292-9. PubMed ID: 23525574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Behçet's disease associated with Crohn's disease].
    Houman H; Ben Dahmen F; Ben Ghorbel I; Chouaib S; Lamloum M; Kchir N; Ben Ammar A; Miled M
    Ann Med Interne (Paris); 2001 Nov; 152(7):480-2. PubMed ID: 11965089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term efficacy of adalimumab in paediatric Crohn's disease patients naïve to other anti-TNF therapies.
    Martín-de-Carpi J; Pociello N; Varea V
    J Crohns Colitis; 2010 Nov; 4(5):594-8. PubMed ID: 21122566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
    Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
    Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
    Sandborn WJ; Hanauer SB; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh DG; Panaccione R; Wolf D; Kent JD; Bittle B; Li J; Pollack PF
    Gut; 2007 Sep; 56(9):1232-9. PubMed ID: 17299059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adalimumab versus azathioprine to halt the progression of bowel damage in Crohn's disease: application of Lémann Index.
    Ribaldone DG; Caviglia GP; Pellicano R; Vernero M; Italia A; Morino M; Saracco GM; Astegiano M
    Scand J Gastroenterol; 2019 Nov; 54(11):1339-1345. PubMed ID: 31692395
    [No Abstract]   [Full Text] [Related]  

  • 36. Guillain-Barrè syndrome after treatment with human anti-tumor necrosis factorα (adalimumab) in a Crohn's disease patient: case report and literature review.
    Cesarini M; Angelucci E; Foglietta T; Vernia P
    J Crohns Colitis; 2011 Dec; 5(6):619-22. PubMed ID: 22115384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adalimumab for the treatment of pediatric Crohn's disease.
    Nuti F; Fiorino G; Danese S
    Expert Rev Clin Immunol; 2015; 11(9):963-72. PubMed ID: 26211396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Biological therapy as treatment of inflammatory bowel diseases].
    Agnholt J
    Ugeskr Laeger; 2008 Jun; 170(24):2152-6. PubMed ID: 18565302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial.
    Louis E; Löfberg R; Reinisch W; Camez A; Yang M; Pollack PF; Chen N; Chao J; Mulani PM
    J Crohns Colitis; 2013 Feb; 7(1):34-43. PubMed ID: 22480772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial.
    Savarino E; Bodini G; Dulbecco P; Assandri L; Bruzzone L; Mazza F; Frigo AC; Fazio V; Marabotto E; Savarino V
    Am J Gastroenterol; 2013 Nov; 108(11):1731-42. PubMed ID: 24019080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.